X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs LUPIN LTD - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA LUPIN LTD DISHMAN PHARMA/
LUPIN LTD
 
P/E (TTM) x 25.1 19.8 127.0% View Chart
P/BV x 3.3 2.7 125.0% View Chart
Dividend Yield % 0.7 0.9 71.0%  

Financials

 DISHMAN PHARMA   LUPIN LTD
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
LUPIN LTD
Mar-17
DISHMAN PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs3741,750 21.4%   
Low Rs1291,384 9.3%   
Sales per share (Unadj.) Rs197.8387.4 51.1%  
Earnings per share (Unadj.) Rs21.256.6 37.4%  
Cash flow per share (Unadj.) Rs34.776.8 45.2%  
Dividends per share (Unadj.) Rs2.007.50 26.7%  
Dividend yield (eoy) %0.80.5 166.0%  
Book value per share (Unadj.) Rs179.9298.9 60.2%  
Shares outstanding (eoy) m80.69451.58 17.9%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x1.34.0 31.5%   
Avg P/E ratio x11.927.7 42.9%  
P/CF ratio (eoy) x7.220.4 35.5%  
Price / Book Value ratio x1.45.2 26.7%  
Dividend payout %9.413.2 71.2%   
Avg Mkt Cap Rs m20,306707,513 2.9%   
No. of employees `0000.816.8 4.9%   
Total wages/salary Rs m5,35528,495 18.8%   
Avg. sales/employee Rs Th19,252.710,418.3 184.8%   
Avg. wages/employee Rs Th6,459.51,697.0 380.7%   
Avg. net profit/employee Rs Th2,064.11,523.0 135.5%   
INCOME DATA
Net Sales Rs m15,961174,943 9.1%  
Other income Rs m2651,065 24.9%   
Total revenues Rs m16,226176,008 9.2%   
Gross profit Rs m4,10344,931 9.1%  
Depreciation Rs m1,0919,122 12.0%   
Interest Rs m9441,525 61.9%   
Profit before tax Rs m2,33435,349 6.6%   
Minority Interest Rs m0-72 0.0%   
Prior Period Items Rs m183 1.3%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6249,785 6.4%   
Profit after tax Rs m1,71125,575 6.7%  
Gross profit margin %25.725.7 100.1%  
Effective tax rate %26.727.7 96.5%   
Net profit margin %10.714.6 73.3%  
BALANCE SHEET DATA
Current assets Rs m11,018119,542 9.2%   
Current liabilities Rs m9,51761,206 15.5%   
Net working cap to sales %9.433.3 28.2%  
Current ratio x1.22.0 59.3%  
Inventory Days Days11076 145.4%  
Debtors Days Days3590 38.8%  
Net fixed assets Rs m16,304131,660 12.4%   
Share capital Rs m161903 17.9%   
"Free" reserves Rs m12,907134,073 9.6%   
Net worth Rs m14,516134,976 10.8%   
Long term debt Rs m4,18956,478 7.4%   
Total assets Rs m29,805266,073 11.2%  
Interest coverage x3.524.2 14.4%   
Debt to equity ratio x0.30.4 69.0%  
Sales to assets ratio x0.50.7 81.4%   
Return on assets %8.910.2 87.5%  
Return on equity %11.818.9 62.2%  
Return on capital %17.519.3 91.0%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95281,885 6.0%   
Fx outflow Rs m69721,506 3.2%   
Net fx Rs m4,25560,378 7.0%   
CASH FLOW
From Operations Rs m2,78641,148 6.8%  
From Investments Rs m-1,529-25,287 6.0%  
From Financial Activity Rs m-9414,332 -21.7%  
Net Cashflow Rs m31620,193 1.6%  

Share Holding

Indian Promoters % 61.4 46.6 131.8%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 3.7 11.3 32.7%  
FIIs % 12.7 31.9 39.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 10.1 218.8%  
Shareholders   46,261 98,259 47.1%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   GSK PHARMA  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  IPCA LABS  NATCO PHARMA  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS